Skip to main content
SpringerLink
Log in

Doping und Medikamentenmissbrauch

  • Chapter
Sportkardiologie

Zusammenfassung

Der Missbrauch von Medikamenten und die Anwendung unerlaubter Methoden zum Zwecke der Leistungssteigerung findet nicht nur im Leistungssport statt, sondern stellt auch im Breiten- und Freizeitsport ein relevantes Problem dar. Doping gilt als Verursacher von Gesundheitsschäden. Für das Herz-Kreislauf-System ist hierbei unter der Einnahme verschiedener Dopingsubstanzen ein breites Spektrum an unerwünschten Wirkungen beschrieben. Diese umfassen unter anderem die Entwicklung einer Myokardhypertrophie, das Auftreten von Arrhythmien, eine Dyslipoproteinämie, proatherogene Effekte bis hin zum Myokardinfarkt und den plötzlichen Herztod. Die Kenntnis des Nebenwirkungsprofils der einzelnen Dopingsubstanzen besitzt auch in der täglichen klinischen Praxis eine besondere Bedeutung, da es bei differenzialdiagnostischen Überlegungen mitberücksichtigt werden muss.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Achar S, Rostamian A, Narayan SM (2010) Cardiac and metabolic effects of anabolic androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol 106: 893–901

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Angell PJ, Chester N, Sculthorpe N, Whyte G, George K, Somauroo J (2012) Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician. Br J Sports Med 46 (Suppl 1):i78–84

    Article  PubMed  Google Scholar 

  3. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Picard MH, Hutter AM Jr, Pope HG Jr (2010) Long-term anabolicandrogenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail 3:472–476

    Article  PubMed  PubMed Central  Google Scholar 

  4. Buettner A, Thieme D (2010) Side effects of anabolic androgenic steroids: Pathological findings and structure - activity relationships. In: Doping in Sports, Handbook of Experimental Pharmacology. Springer, Heidelberg, S 459–484

    Google Scholar 

  5. D’Andrea A, Caso P, Salerno G, Scarafile R, De CG, Mita C, Di SG, Severino S, Cuomo S, Liccardo B, Esposito N, Calabro R (2007) Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br J Sports Med 41:149–155

    Article  PubMed  Google Scholar 

  6. D’Ascenzo S, Millimaggi D, Di MC, Saccani-Jotti G, Botre F, Carta G, Tozzi-Ciancarelli MG, Pavan A, Dolo V (2007) Detrimental effects of anabolic steroids on human endothelial cells. Toxicol Lett 169:129–136

    Article  PubMed  Google Scholar 

  7. Deligiannis A, Björnstad H, Carre F, Heidbüchel H, Kouidi E, Panhuyzen-Goedkoop NM, Pigozzi F, Schänzer W, Vanhees L (2006) ESC Study Group of Sports Cardiology: ESC study group of sports cardiology position paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil 13:687–694

    Article  PubMed  Google Scholar 

  8. Dhar R, Stout CW, Link MS, Homoud MK, Weinstock J, Estes NA III (2005) Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc 80:1307–1315

    Article  CAS  PubMed  Google Scholar 

  9. Dietz P, Ulrich R, Dalaker R, Striegel H, Franke AG, Lieb K, Simon P (2013) Associations between Physical and Cognitive Doping - A Cross-Sectional Study in 2.997 Triathletes. PLoS One 8:e78702

    Article  PubMed  PubMed Central  Google Scholar 

  10. Di Paolo M, Agozzino M, Toni C, Luciani AB, Molendini L, Scaglione M, Inzani F, Pasotti M, Buzzi F, Arbustini E (2007) Sudden anabolic steroid abuse-related death in athletes. Int J Cardiol 114:114–117

    Article  PubMed  Google Scholar 

  11. Dunn M, Thomas JO, Swift W, Burns L (2012) Elite athletes' estimates of the prevalence of illicit drug use: evidence for the false consensus effect. Drug Alcohol Rev 31:27–32

    Article  PubMed  Google Scholar 

  12. Ebenbichler CF, Sturm W, Gänzer H, Bodner J, Mangweth B, Ritsch A, Sandhofer A, Lechleitner M, Föger B, Patsch JR (2001) Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 158:483–490

    Article  CAS  PubMed  Google Scholar 

  13. Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G, Karch SB (2007) Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med 121:48–53

    Article  PubMed  Google Scholar 

  14. Golestani R, Slart RH, Dullaart RP, Glaudemans AW, Zeebregts CJ, Boersma HH, Tio RA, Dierckx RA. Adverse cardiovascular effects of anabolic steroids: pathophysiology imaging. Eur J Clin Invest. 2012, 42:795–803

    Article  CAS  PubMed  Google Scholar 

  15. Harmer PA. Anabolic-androgenic steroid use among young male and female athletes: is the game to blame? Br J Sports Med. 2010, 44: 26–31

    Article  CAS  PubMed  Google Scholar 

  16. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH (2004) Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 38:253–259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Heuberger JA, Cohen Tervaert JM, Schepers FM, Vliegenthart AD, Rotmans JI, Daniels JM, Burggraaf J, Cohen AF (2013) Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit. Br J Clin Pharmacol 75:1406–1421

    Article  CAS  PubMed  Google Scholar 

  18. Holt RI, Sonksen PH: Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol. 2008, 154: 542–556

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Montisci M, El Mazloum R, Cecchetto G, Terranova C, Ferrara SD, Thiene G, Basso C (2012) Anabolic andreogenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic Sci Int 217:e13–e18

    Article  CAS  PubMed  Google Scholar 

  20. Mouhaffel AH, Madu EC, Satmary WA, Fraker TD Jr (1995) Cardiovascular complications of cocaine. Chest 107:1426–1434

    Article  CAS  PubMed  Google Scholar 

  21. Müller-Platz C, Boos C, Müller RK (2006) Doping beim Freizeit- und Breitensport. Gesundheitsberichterstattung des Bundes Heft 34

    Google Scholar 

  22. Niess, Am, Striegel H, Wiesing U (2014) Doping und Medikamentenmissbrauch im Breiten- und Freizeitsport: Stellungnahme der Sektion Breiten-, Freizeit- und Alterssport der DGSP. Dtsch Z Sportmed, 65: 29–33

    CAS  Google Scholar 

  23. Parkinson AB, Evans NA (2006) Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 38:644–651

    Article  CAS  PubMed  Google Scholar 

  24. Perera NJ, Steinbeck KS, Shackel N (2013) The adverse health consequences of the use of multiple performance-enhancing substances–a deadly cocktail. J Clin Endocrinol Me 98:4613–4618

    Article  CAS  Google Scholar 

  25. Piloto N, Teixeira HM, Teixeira-Lemos E, Parada B, Garrido P, Sereno J, Pinto R, Carvalho L, Costa E, Belo L, Santos-Silva A, Teixeira F, Reis F (2009) Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic sports doping. Cardiovasc Toxicol 9:201–210

    Article  CAS  PubMed  Google Scholar 

  26. Pitsch W, Emrich E, Klein M (2007) Doping in elite sports in Germany: results of a www-survey. European Journal for Sport and Society 4:89–102

    Google Scholar 

  27. Pope HG Jr, Wood R, Rogol A, Nyberg F, Bowers L, Bhasin S (2014) Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement. Endocr Rev Jan 1: er20131058. [Epub ahead of print]

    Google Scholar 

  28. Scarpino V, Arrigo A, Benzi G, Garattini S, La Vecchia C, Bernardi LR, Silvestrini G, Tuccimei G (1990) Evaluation of prevalence of «doping” among Italian athletes. Lancet 336:1048–1050

    Article  CAS  PubMed  Google Scholar 

  29. Schwartz BG, Rezkalla S, Kloner RA (2010) Cardiovascular effects of cocaine. Circulation 122:2558–2569

    Article  PubMed  Google Scholar 

  30. Sjöqvist F, Garle M, Rane A (2008) Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 371:1872–1882

    Article  PubMed  Google Scholar 

  31. Striegel H, Simon P, Frisch S, Roecker K, Dietz K, Dickhuth HH, Ulrich R (2006) Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend 81:11–19

    Article  PubMed  Google Scholar 

  32. Striegel H, Ulrich R, Simon P. Randomized response estimates for doping and illicit drug use in elite athletes. Drug Alcohol Depend. 2010, 106: 230–232

    Article  PubMed  Google Scholar 

  33. Stubbe JH, Chorus AM, Frank LE, de Hon O, van der Heijden PG (2013) Prevalence of use of performance enhancing drugs by fitness centre members. Drug Test Anal Sep 9. doi: 10.1002/dta.1525. [Epub ahead of print]

    Google Scholar 

  34. Urhausen A, Albers T, Kindermann W (2004) Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 90:496–501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Vanberg P, Atar D (2010) Androgenic anabolic steroid abuse and the cardiovascular system. Handb Exp Pharmacol 195:411–457

    Article  CAS  Google Scholar 

  36. World Anti-Doping Agency (WADA) (2009) World Anti-Doping Code. http://www.wada-ama.org Zugegriffen am: 10.1.2014

  37. World Anti-Doping Agency (WADA) Testing report: http://www.wada-ama.org/Docu-ments/Resources/Testing-Figures/WADA-2012-Anti-Doping-Testing-Figures-ReportEN.pdf. Zugegriffen am: 0.1.2014

  38. Zaugg M, Jamali NZ, Lucchinetti E, Xu W, Alam M, Shafiq SA, Siddiqui MA (2001) Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol 187:90–95

    Article  CAS  PubMed  Google Scholar 

  39. Zentrale Ethikkommission bei der Bundesärztekammer: Stellungnahme der Zentralen Kommission zur Wahrung ethischer Grundsätze in der Medizin und ihren Grenzgebieten (Zentrale Ethikkommission) bei der Bundesärztekammer zur Doping und ärztliche Ethik (2009) Deutsches Ärzteblatt 106:A360–A364

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Tübingen Sportmedizin, Hoppe-Seyler-Straße 6, 72076, Tübingen, Deutschland

    Dr. med. Andreas Nieß (Ärztlicher Direktor)

Authors
  1. Dr. med. Andreas Nieß
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. FA Innere Medizin, Kardiologie, Sportmedizin Universitätsinstitut für präventive und rehabilitative Sportmedizin Forschungsinstitut für molekulare Sport- und Rehabilitationsmedizin Paracelsus Medizinische Privatuniversität Salzburg Institut für Sportmedizin des Landes Salzburg Sportmedizin, Olympiazentrums Salzburg-Rif, 5020, Salzburg, Österreich

    Josef Niebauer

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Nieß, A. (2015). Doping und Medikamentenmissbrauch. In: Niebauer, J. (eds) Sportkardiologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43711-7_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43711-7_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43710-0

  • Online ISBN: 978-3-662-43711-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation